Microsoft word - docslib-#1328965-v1-settlement_-_schedule_j_-_short_notice…

HAVE YOU USED
ZYPREXA (OLANZAPINE))?
IF YOU OR SOMEONE CLOSE TO YOU HAS USED ZYPREXA (OLANZAPINE) PRIOR TO
JUNE 6, 2007, PLEASE READ THIS NOTICE CAREFULLY AS IT MAY AFFECT YOUR LEGAL RIGHTS AND YOU MAY BE ELIGIBLE FOR COMPENSATION ZYPREXA (olanzapine) is an antipsychotic drug which is prescribed for the treatment of schizophrenia and related psychotic disorders and bipolar I
disorder.
Class action lawsuits were initiated in Ontario, British Columbia and Quebec, alleging that Eli Lilly Canada Inc. and Eli Lilly and Company (the "Defendants") negligently manufactured, marketed and sold ZYPREXA (olanzapine) without properly warning of alleged risks of diabetes and related disorders such as hyperglycemia, ketoacidosis and pancreatitis. The Defendants deny the plaintiffs' allegations and deny any wrongdoing or liability. The court has not taken any position as to the truth or merits of the claims or defences asserted by either side. The allegations made by the plaintiffs have not been proven in court. If you, or a family member in your care, ingested ZYPREXA (olanzapine) prior to June 6, 2007 and developed diabetes, hyperglycemia, ketoacidosis or
pancreatitis potentially associated with its use, you may be eligible to receive compensation.
A Settlement Agreement has been reached and approved by the courts. If you or someone close to you used ZYPREXA (olanzapine) prior to June 6,
2007, you should immediately review the full legal notice in this matter to ensure you understand your legal rights. A copy of the full legal notice and
the claim form can be viewed at www.classaction.ca (English and French), www.classproceedings.ca, and www.poynerbaxter.com or can be obtained
from contacting Class Counsel as listed below or by contacting the Claims Administrator.
This notice does not constitute medical advice. Patients who have been prescribed ZYPREXA should consult with their physicians if they have any
questions with respect to their medical condition and should not stop taking ZYPREXA without consulting their health care professional.
Claim forms must be completed by October 28, 2010. The Claims Administrator can be reached at 1-877-739-8933.
Class Counsel can be reached as follows: Siskinds LLP
Poyner Baxter, LLP
In all provinces other 680 Waterloo Street
In British
408-145 Chadwick Court
than British Columbia London ON N6A 3V8
Columbia:
North Vancouver, BC V7M 3K1
and Quebec:
Stevensons LLP
Siskinds, Desmeules,LLP
144 Front Street West, Suite 400
In Quebec:
43 Rue Buade, Bur 320
Toronto, ON M5J 2L7
Quebec City, Quebec G1R 4A2
Email: nathalie.boulay@siskindsdesmeules.com PUBLICATION OF THIS NOTICE HAS BEEN AUTHORIZED BY THE
ONTARIO, QUEBEC AND BRITISH COLUMBIA COURTS

Source: http://www.poynerbaxter.com/Zyprexa-Zyprexa-Short-Form-Notice2.pdf